Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31274808 | 0.94 | NAMPT (0.48) | NAMPTDDB1CRBNGPR119JAK2 | |
| SCHEMBL31037491 | 0.94 | NAMPT (0.48) | NAMPTDDB1CRBNGPR119JAK2 | |
| SCHEMBL7499165 | 0.84 | NAMPT (0.54) | NAMPTDDB1CRBNGPR119JAK2 | |
| SCHEMBL28415386 | 0.83 | FAAH (0.47) | GPR119KDM4EMAPT | |
| SCHEMBL6132557 | 0.83 | GPR119 (0.64) | NAMPTDDB1CRBNGPR119JAK2 | |
| SCHEMBL12378795 | 0.83 | NAMPT (0.57) | NAMPTDDB1CRBNGPR119JAK2 | |
| SCHEMBL15554611 | 0.82 | SCD5 (0.41) | SMN1; SMN2 | |
| SCHEMBL17275228 | 0.82 | FAAH (0.48) | GPR119THRBKDM4EGAASMN1; SMN2 | |
| SCHEMBL12416079 | 0.81 | NAMPT (0.58) | NAMPTDDB1CRBNGPR119THRB | |
| SCHEMBL7049681 | 0.81 | NAMPT (0.50) | NAMPTDDB1CRBNGPR119JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4722208-A1 | NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4663628-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024246764-A1 | NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024166024-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-08-15 | — | — | WO | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428502-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015095767-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | 3-V BIOSCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014008197-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | NAMPT 705/4885DDB1 2713/4885CRBN 4787/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | NAMPT 4562/4885DDB1 389/4885CRBN 8/4885 |
| US-20150210688-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | NAMPT 235/4885DDB1 3310/4885CRBN 3544/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | NAMPT 4261/4885DDB1 809/4885CRBN 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.